Alpha Teknova, Inc. Announces the Opening of New GMP-Certified Production Facility
August 09, 2023 at 08:00 am EDT
Share
Alpha Teknova, Inc. announced the opening of their newest GMP-certified production facility, enabling bioprocessing and gene therapy companies to get into the clinic faster. Located in Hollister, California, the Company?s modular manufacturing facility recently received ISO 13485:2016 certification for the production of GMP-grade products. Previously operational for research-grade production, the new facility adds more than 10,000 square feet of GMP-certified ISO cleanrooms and provides a three-fold increase in overall manufacturing capacity.
With expanded formulation, dispensing, cleanroom, and warehouse space ? including increased automation to support single-use needs and animal-free and endotoxin-controlled environments ? the new GMP-certified facility exemplifies Teknova?s modular manufacturing platform, further enabling the flexible, scalable, and consistent production of high-quality reagents that the Company is known for.
Bioprocessing and gene therapy companies are now able to work with one trusted partner across the entire clinical pipeline, accelerating their breakthroughs as they transition from RUO to GMP.
Alpha Teknova, Inc. is a producer of critical reagents for the research, discovery, development, and commercialization of therapies, vaccines, and molecular diagnostics. It offers two primary business lines, which include lab essentials and clinical solutions. It also offers three primary product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. The Company offers its liquid cell culture media and supplements and molecular biology reagents in both of its two product categories; pre-poured media plates are available in its Lab Essentials category only. Its customers include pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions developing vaccines and therapies and performing basic research.